Life Sciences Tools and Services
Company Overview of Antitope Limited
Antitope Limited, a biotechnology research company, develops non-immunogenic protein therapeutics. The company provides immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. It offers EpiScreen, an ex vivo human T cell assay technology for predicting the immunogenicity of biologics or for identifying T cell epitopes within the sequences of biologics; Composite Human Antibody technology for generating humanized antibodies devoid of human T cell epitopes; and Composite Protein technology for generating therapeutic proteins devoid of human T cell epitopes. The company also provides pANT Vector System, an expression system to enhance expressio...
Babraham Research Campus
Cambridge, CB22 3AT
Founded in 2004
Key Executives for Antitope Limited
Antitope Limited does not have any Key Executives recorded.
Antitope Limited Key Developments
Antitope Limited Enters into an Agreement with Apitope
May 19 15
Antitope Limited has entered into an agreement with Apitope Under the agreement, Antitope will investigate and measure the immunological status of haemophilia A patients after treatment. Apitope's patented discovery platform enables selection of potential disease-modifying peptide therapies for the autoimmune disease of interest. It has a pipeline of compounds in development including ATX-F8-117, which has been designed to induce immune tolerance to blood coagulation factor VIII in haemophilia A patients. Haemophilia A is caused by a deficiency in blood coagulation factor VIII and is treated with replacement factor VIII protein. About 30% of haemophilia A patients develop neutralising antibodies to factor VIII which inhibits its activity and thus renders treatment less effective. Such patients are at risk of serious and life-threatening bleeding.
Antitope Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Antitope Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Antitope, INSERM and Baylor Institute to Collaborate to Produce Manufacturing Cell Lines for Two Novel Vaccines for HIV
Jan 13 15
Antitope Limited announced that it has extended its relationship with INSERM, ANRS and the Baylor Institute for Immunology Research. INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) using monoclonal antibodies fused to HIV antigens. Extensive preclinical data has demonstrated the high immunogenicity of the candidate vaccines. Antitope will produce cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins that INSERM-ANRS and BIIR are developing as potential therapeutic and prophylactic vaccines to treat HIV. The cell lines will be produced using Antitope’s Composite CHO™ technology. The antibody component of the fusion proteins has previously been humanized by Antitope using its Composite Human Antibody™ technology. Phase I and Phase II clinical trials will be conducted in France to test the immunogenicity and efficacy of these DC-targeting vaccines developed by INSERM-ANRS in partnership with the BIIR.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries